- Academic Registry
Programme & Unit Catalogues


BB30230: Cancer therapeutics

[Page last updated: 15 October 2020]

Follow this link for further information on academic years Academic Year: 2020/1
Further information on owning departmentsOwning Department/School: Department of Biology & Biochemistry
Further information on credits Credits: 6      [equivalent to 12 CATS credits]
Further information on notional study hours Notional Study Hours: 120
Further information on unit levels Level: Honours (FHEQ level 6)
Further information on teaching periods Period:
Semester 2
Further information on unit assessment Assessment Summary: CW 100%
Further information on unit assessment Assessment Detail:
  • Coursework (CW 100%)
Further information on supplementary assessment Supplementary Assessment:
BB30230 Re-assessment Essay (where allowed by programme regulations)
Further information on requisites Requisites: Before taking this module you are advised to take BB20023
Description: Aims:
To provide students with:
* A thorough understanding of the scientific basis underlying the principles and practice of cancer therapeutics
* A critical overview of the biology behind the development and evaluation of current and emerging treatments for cancer.

Learning Outcomes:
After taking this course the student should be able to:
* Demonstrate a thorough knowledge of the molecular and microenvironmental differences between cancer and normal tissues
* Explain how these differences are exploited in drug design for cancer treatment
* Critically evaluate current and emerging therapies against cancer.

Skills:
Learning and studying T/F/A, information handling and retrieval T/F/A, working independently T/F, written communication T/F/A, oral communication T/F/A.

Content:
Molecular and cellular cancer pathways associated with the tumour microenvironment or growth, which underpin current cancer treatments including;
* Genetic screening
* Radiotherapy, chemotherapy and adjuvant therapies
* Emerging therapies such as immunotherapy, angiotherapy and other small molecule therapies based on the translation of innovative cancer biology research into lead and preclinical stage drug candidates.
Further information on programme availabilityProgramme availability:

BB30230 is Optional on the following programmes:

Department of Biology & Biochemistry
  • USBB-AFB02 : BSc(Hons) Biochemistry (Year 3)
  • USBB-AKB06 : BSc(Hons) Biochemistry with Professional Placement (Year 4)
  • UXXX-AFB11 : BSc(Hons) Biomedical Sciences (Year 3)
  • UXXX-AKB11 : BSc(Hons) Biomedical Sciences with Professional Placement (Year 4)
  • USBB-AKB08 : BSc(Hons) Molecular and Cellular Biology with Professional Placement (Year 4)

Notes:

  • This unit catalogue is applicable for the 2020/21 academic year only. Students continuing their studies into 2021/22 and beyond should not assume that this unit will be available in future years in the format displayed here for 2020/21.
  • Programmes and units are subject to change in accordance with normal University procedures.
  • Availability of units will be subject to constraints such as staff availability, minimum and maximum group sizes, and timetabling factors as well as a student's ability to meet any pre-requisite rules.
  • Find out more about these and other important University terms and conditions here.